170 related articles for article (PubMed ID: 38091293)
1. Rational design of proteasome inhibitors based on the structure of the endogenous inhibitor PI31/Fub1.
Velez B; Razi A; Hubbard RD; Walsh R; Rawson S; Tian G; Finley D; Hanna J
Proc Natl Acad Sci U S A; 2023 Dec; 120(51):e2308417120. PubMed ID: 38091293
[TBL] [Abstract][Full Text] [Related]
2. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
3. Yeast PI31 inhibits the proteasome by a direct multisite mechanism.
Rawson S; Walsh RM; Velez B; Schnell HM; Jiao F; Blickling M; Ang J; Bhanu MK; Huang L; Hanna J
Nat Struct Mol Biol; 2022 Aug; 29(8):791-800. PubMed ID: 35927584
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
5. Site-Specific Proteasome Inhibitors.
Kisselev AF
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053202
[TBL] [Abstract][Full Text] [Related]
6. Entinostat-Bortezomib Hybrids against Multiple Myeloma.
Ferro A; Graikioti D; Gezer E; Athanassopoulos CM; Cuendet M
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771118
[TBL] [Abstract][Full Text] [Related]
7. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.
Kegyes D; Gulei D; Drula R; Cenariu D; Tigu B; Dima D; Tanase A; Badelita S; Buzoianu AD; Ciurea S; Ghiaur G; Terpos E; Ciechanover A; Einsele H; Tomuleasa C
Blood Rev; 2023 Sep; 61():101100. PubMed ID: 37291017
[TBL] [Abstract][Full Text] [Related]
9. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
10. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
11. Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance.
Leonardo-Sousa C; Carvalho AN; Guedes RA; Fernandes PMP; Aniceto N; Salvador JAR; Gama MJ; Guedes RC
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408601
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of microbial proteasome inhibitors.
Momose I; Kawada M
Int Immunopharmacol; 2016 Aug; 37():23-30. PubMed ID: 26589840
[TBL] [Abstract][Full Text] [Related]
13. Development of proteasome inhibitors as research tools and cancer drugs.
Goldberg AL
J Cell Biol; 2012 Nov; 199(4):583-8. PubMed ID: 23148232
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
15. Differential Interactions of the Proteasome Inhibitor PI31 with Constitutive and Immuno-20S Proteasomes.
Wang J; Kjellgren A; DeMartino GN
Biochemistry; 2024 Apr; 63(8):1000-1015. PubMed ID: 38577872
[TBL] [Abstract][Full Text] [Related]
16. Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma.
Ubels J; Sonneveld P; van Vliet MH; de Ridder J
Clin Cancer Res; 2020 Nov; 26(22):5952-5961. PubMed ID: 32913136
[TBL] [Abstract][Full Text] [Related]
17. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
18. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
Downey-Kopyscinski SL; Srinivasa S; Kisselev AF
Sci Rep; 2022 Jul; 12(1):12788. PubMed ID: 35896610
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
Allmeroth K; Horn M; Kroef V; Miethe S; Müller RU; Denzel MS
Leukemia; 2021 Mar; 35(3):887-892. PubMed ID: 32690882
[No Abstract] [Full Text] [Related]
20. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
